

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 August 2006 (17.08.2006)

PCT

(10) International Publication Number
WO 2006/084757 A3

(51) International Patent Classification:

A61P 3/10 (2006.01) A61K 31/41 (2006.01)
A61P 19/10 (2006.01) A61K 31/40 (2006.01)
A61P 9/12 (2006.01) A61K 45/06 (2006.01)

(21) International Application Number:

PCT/EP2006/001285

(22) International Filing Date:

13 February 2006 (13.02.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0503062.2 14 February 2005 (14.02.2005) GB

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **GLASSPOOL, John** [GB/CH]; Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel (CH).

(74) Agent: **DE WEER, Peter**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report

(88) Date of publication of the international search report:

23 November 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION OF CA/MG SALT OF VALSARTAN WITH AN ANTIDIABETIC AGENT

(57) Abstract: The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises (i) the calcium or magnesium salt of the AT₁ receptor antagonist (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2¹-(1 H-tetrazol-5-yl)-biphenyl-4-yl-methyl]-amine (valsartan) and (ii) at least one antidiabetic compound, preferably selected from the group consisting of a dipeptidyl peptidase IV (DPP IV) inhibitor, insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α -glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α_2 -adrenergic antagonists.

WO 2006/084757 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/001285

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61P3/10 A61P19/10 A61P9/12 A61K31/41 A61K31/40
A61K45/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 03/099279 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; HOLMES, DAVID, GRENVILLE; SHETTY, S) 4 December 2003 (2003-12-04) page 17, paragraph 4 - paragraph 6 page 20, paragraph 4 claims 5,7	1-12
Y	WO 02/06253 A (NOVARTIS AG; NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H; MARTI) 24 January 2002 (2002-01-24) cited in the application claims 3,4 ----- -/--	1-12

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

10 August 2006

Date of mailing of the international search report

21/08/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Olausson, J

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/001285

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	"HIGHLIGHTS OF THE 37TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD)" PRACTICAL DIABETES INTERNATIONAL, PROFESSIONAL, MANAGERIAL AND HEALTHCARE PUBLICATIONS,, GB, vol. 18, no. 9, November 2001 (2001-11), pages 332-337, XP008011490 ISSN: 1357-8170 page 335, column 3 -----	1-12
A	"Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats." JOURNAL OF HYPERTENSION, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 21, 2003, pages 761-769, XP008067334 ISSN: 0263-6352 page 765, column 2 - page 767, column 1 -----	1-12
P,X	LEDINGHAM JM AND LAVERTY R: "Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats." CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, XX, XX, vol. 32, no. 11, 2005, pages 919-925, XP008067346 table 1 -----	1-12
P,Y	WO 2005/025673 A (FOLLI, FRANCO; MANFREDI, PAOLO; GONZALES, GILBERT) 24 March 2005 (2005-03-24) claims 1,6,12 -----	1-12
P,Y	WO 2005/084666 A (ABEILLE PHARMACEUTICALS, INC; BORSADIA, SURESH) 15 September 2005 (2005-09-15) claims 1,51 -----	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2006/001285

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03099279	A	04-12-2003	AU 2003242593 A1	12-12-2003
			BR 0311397 A	15-03-2005
			CA 2487167 A1	04-12-2003
			CN 1655786 A	17-08-2005
			EP 1511484 A1	09-03-2005
			JP 2005532330 T	27-10-2005
			MX PA04011785 A	31-03-2005
			US 2006074058 A1	06-04-2006
WO 0206253	A	24-01-2002	AU 8967201 A	30-01-2002
			BR 0112665 A	24-06-2003
			CA 2415962 A1	24-01-2002
			CN 1443176 A	17-09-2003
			CN 1680341 A	12-10-2005
			CZ 20030117 A3	14-05-2003
			HU 0300731 A2	29-09-2003
			JP 2004504307 T	12-02-2004
			MX PA03000525 A	14-05-2003
			NO 20030232 A	17-01-2003
			NZ 523557 A	24-12-2004
			PL 360737 A1	20-09-2004
			RU 2275363 C2	27-04-2006
			SK 552003 A3	01-07-2003
			US 2003207930 A1	06-11-2003
			ZA 200300285 A	25-03-2004
WO 2005025673	A	24-03-2005	CA 2538333 A1	24-03-2005
			EP 1663395 A1	07-06-2006
			US 2005054731 A1	10-03-2005
WO 2005084666	A	15-09-2005	NONE	